{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '7.4.2.3', 'Reporting and Follow-up Requirements for Pregnancies', 'Pregnancies in Female Subjects', 'A urine pregnancy test will be conducted on all females of childbearing potential as', 'presented in the Schedule of Events (Table 1).', 'If a subject becomes pregnant after the administration of any study treatment, R-Pharm', \"International and/or R-Pharm International's designee should be informed immediately.\", 'Study treatment should be discontinued as soon as the pregnancy is known, and the following', 'should be completed:', 'The subject should immediately discontinue further administration of study treatment.', 'The subject should return for an EoT Visit.', 'All scheduled safety assessments must be performed unless contraindicated by', 'pregnancy (harmful to fetus) or the subject withdraws informed consent.', 'The Investigator must inform the subject of information currently known about potential', 'risks and about available treatment alternatives. The pregnancy should be followed up to', 'determine outcome including spontaneous or voluntary termination, details of the birth, and', 'the presence or absence of any birth defects, congenital abnormalities, or maternal and/or', 'newborn complications.', 'Full details will be recorded on a Pregnancy Report eCRF and submitted via the Electronic', 'Data Capture (EDC) system, and reporting details will be detailed in the Study Manual. The', 'Investigator will update the Pregnancy Report eCRF with additional information as soon as', 'the outcome of the pregnancy is known.', 'If the outcome of the pregnancy is an SAE then this must be additionally reported as an SAE', 'on the appropriate eCRF page.', 'Pregnancies in Female Partners of Male Subjects', 'Male subjects will be instructed through the ICF to immediately inform the Investigator if', 'their partner becomes pregnant during the study and up to 3 months after the subject received', 'the last injection of study treatment. A Pregnancy Report eCRF should be completed by the', 'Investigator within 1 working day after learning of the pregnancy and submitted via the EDC', 'system. Attempts should be made to collect and report details of the course and outcome of', 'any pregnancy in the partner of a male subject exposed to the study treatment. The pregnant', 'partner will need to sign an Authorization for Use and Disclosure of Pregnancy Health', 'Information to allow for follow-up on her pregnancy. Once the authorization has been', 'Amendment 2: 06 March 2019', '102', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'signed, the Investigator will update the Pregnancy Report eCRF with additional information', 'on the course and outcome of the pregnancy. An Investigator who is contacted by the male', 'subject or his pregnant partner may provide information on the risks of the pregnancy and the', 'possible effects on the fetus, to support an informed decision in cooperation with the treating', 'physician and/or obstetrician.', '7.4.3', 'Adverse Events of Special Interest', 'The following safety concerns were identified as AESIs based upon either the safety data', \"available to date (refer to the most recent version of the Investigator's Brochure) for OKZ or\", 'drug class-related events for a biologic IL-6 inhibitor:', 'Infections (particularly serious infections), including TB and opportunistic infections', '-', 'Confirmed cases of active TB must also be recorded as an SAE.', 'Malignancies', '- The Investigator will be asked to provide relevant medical', 'information/documentation (e.g., pathology/histology reports) on all malignancy', 'cases, whether considered serious or not, as these cases will be recorded in the safety', 'database.', 'Elevation of blood lipids (e.g., hypercholesterolemia, blood cholesterol increased,', 'blood triglycerides increased, hypertriglyceridemia, and elevation of LDL)', 'Systemic injection reactions and hypersensitivity reactions, including anaphylaxis', '- Refer to Appendix 3 (Section 13.3) for details on diagnosing anaphylaxis.', 'GI perforation', 'CV events', 'Neutropenia, thrombocytopenia, leukocytopenia, and pancytopenia', 'Hepatotoxicity', '-', 'The Investigator will be asked to provide relevant medical', 'information/documentation (e.g., laboratory test results, including tests for viral', 'hepatitis and, if performed, liver biopsy) on all hepatotoxicity cases, whether', 'considered serious or not, as these cases will be recorded in the safety database (see', 'Section 7.4.3.4).', 'Injection site reactions', 'Amendment 2: 06 March 2019', '103', 'Confidential']\n\n###\n\n", "completion": "END"}